FridayJun 23, 2023 11:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Enters New Stage With Dedicated AI Development Division

Texas-headquartered Freight Technologies (aka Fr8Tech) is a technology innovation company dedicated to sustaining over-the-road (“OTR”) commercial shipments within the USMCA (formerly NAFTA) North American trading area The company’s core Fr8App product is a cloud-based freight matching platform that uses artificial intelligence and machine learning to help shippers and carriers match up their loads, capacity, and destinations Fr8Tech is growing its artificial intelligence development, appointing Dr. Umberto León-Domínguez to oversee the creation of a dedicated AI department Fr8App was recently cited by Google Maps Platform’s blog as an innovative use of advanced markers from the platform to interactively help end users…

Continue Reading

FridayJun 23, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) CMO Discusses Recent Company Announcements in Bell2Bell Podcast Episode

Genprex Chief Medical Officer, Dr. Mark Berger, was featured in a recent Bell2Bell Podcast episode, where he discussed the company’s recent announcements In May, the company received Safety Review Committee (“SRC”) approval to advance to the Phase 2 expansion portion of its Acclaim-1 clinical trial of its lead candidate, REQORSA(R) Immunogene Therapy The Phase 1 dose escalation portion of the study showed that REQORSA(R) was generally well tolerated, and there were no dose-limiting toxicities; Genprex also reported encouraging evidence of efficacy in this portion In April, Genprex announced that its research collaborators presented in vivo mouse data showing that Genprex’s…

Continue Reading

FridayJun 23, 2023 9:00 am

Cepton, Inc. (NASDAQ: CPTN) Expands Collaboration with NVIDIA, Releases New Financial Update Revealing Progress on Volume Production

Cepton integrated Vista-X120 Plus lidar into NVIDIA Omniverse platform to enable real-time simulation and 3D visualization to streamline lidar deployment processes and reduce cost for automakers Vista-X120 Plus features a software-definable ROI, allows users to dynamically adjust and optimize lidar performance and power consumption based on specific scenarios or areas that require additional attention Cepton released a financial update revealing it was on track to receive final production validation for salable vehicles and continue shipment of pre-production lidar units for multiple vehicle models Additional update highlights included completed implementation of embedded lidar software, and execution of RFQ and RFI responses…

Continue Reading

ThursdayJun 22, 2023 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Findings in Diabetes Animal Study and Two Other R&D Programs

Diabetes – Blood glucose levels reduced by 19.9% with patented DehydraTECH(TM) processed CBD Epilepsy – Lower dosages of DehydraTECH-CBD were needed to achieve the same results of Epidiolex(R) in the company’s animal epilepsy study Dementia – Lexaria determined that a longer testing duration is needed for DehydraTECH-CBD in cognition studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, including the company’s patented DehydraTECH(TM) technology, recently reported additional findings from its diabetes animal study DIAB-A22-1, as well as updates on two other applied R&D programs for dementia (DEM-A22-1) and epilepsy (EPIL-A21-1). In March, Lexaria announced that it had…

Continue Reading

WednesdayJun 21, 2023 9:00 am

Cepton, Inc. (NASDAQ: CPTN) Reveals Use of Lidar Technology in Texas & Utah Traffic Initiative; Announces Hire of Luis Gonçalves as Director of Customer Programs

Cepton recently revealed that its lidar technology has been deployed to bolster traffic infrastructure in Texas and Utah The announcement marks a continued trend, which has seen Cepton’s lidar solutions increasingly used to facilitate traffic management and smart city infrastructure – most recently announcing their multi-million contract with a leading U.S. tolling system operator With the company seeing growing business opportunities, as well as being fully committed to executing its flagship lidar series production program by a Top 3 automotive OEM, Cepton has looked to take the next step in its journey with the addition of Luis Gonçalves to its…

Continue Reading

TuesdayJun 20, 2023 10:15 am

Genprex Inc. (NASDAQ: GNPX) CMO Video Discusses Advances in Company’s Fight Against Tumors

U.S.-based gene therapy developer Genprex, Inc. is dedicated to finding more effective and novel solutions for battling cancer (particularly lung cancers) and diabetes Genprex utilizes a propriety platform that encapsulates tumor-suppressing genes within lipid nanoparticles that are injected intravenously The company has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for its two non-small cell lung cancer (“NSCLC”) programs using its drug candidate, REQORSA(R) Genprex also expects to begin a third trial using its REQORSA therapy against small cell lung cancer (“SCLC”) later this year The company recently used its proprietary nanoparticle delivery system, Oncoprex(R), in…

Continue Reading

TuesdayJun 20, 2023 9:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Shares anticipated 0-200% Revenue Growth for 2023; Reports Highest Monthly Increase in New Clients during month of March

Fr8Tech’s management recently shared its updated 2023 revenue guidance of $25-30 million, representing as much as nearly 20% growth from the previous year’s full-year revenue The growth will be fueled, in part, by the uptake of its services, with the company having posted the highest monthly increase in new client sign-ups since the launch of the Fr8App platform Following the recent 10 to 1 reverse share split necessary for Fr8Tech to regain Nasdaq compliance, the company showed that the price would need to show 11x growth on the closing price of March 28, 2023 to meet with third party forecasts…

Continue Reading

ThursdayJun 15, 2023 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) May Announcements Show Resolve to Continue Supporting R&D ‘Lifeblood’

In May, Lexaria made a number of positive announcements related to its R&D initiatives In addition to holding its 2023 Annual Meeting, the company completed dosing for its human clinical nicotine study, NIC-H22-1 Lexaria also reported 900% improvements in delivery of DehydraTECH(TM) processed estrogen into blood plasma in an animal study In a human hypertension study, the company announced that its DehydraTECH-CBD formulation resulted in significant reductions in the blood plasma levels of pro-inflammatory biomarkers (IL 8, 10, and 18) These biomarkers are linked to cardiovascular disease (“CVD”) and many other conditions, such as asthma, lung diseases, chronic kidney disease,…

Continue Reading

WednesdayJun 14, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Announces Positive Data From Phase 1 Clinical Trial Evaluating REQORSA(R) Immunogene Therapy for Late-Stage Non-Small Cell Lung Cancer

The positive data from the Acclaim-1 Phase 1 portion of the Phase 1/2 clinical trial has been published in an abstract at the 2023 American Society of Clinical Oncology Annual Meeting, which took place in Chicago, IL and online June 2 – 6, 2023 Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA(R) in combination with Tagrisso(R) The Phase 2 expansion portion of the study is expected to enroll approximately 66 patients – half of which will have only received Tagrisso(R) and the other half receiving Tagrisso(R) and chemotherapy The global lung cancer treatment market is expected to…

Continue Reading

FridayJun 09, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields Most Convincing Evidence for Anti-Inflammatory Actions of CBD with its DehydraTECH(TM)-CBD

Lexaria just announced additional findings from its HYPER-H21-4 human clinical study, highlighting significant reductions in several pro-inflammatory biomarkers associated with cardiovascular disease This has been termed as “the most convincing evidence in humans,” ultimately showcasing the potential of the company’s patented DehydraTECH(TM)-processed CBD Other third-party research studies have failed to demonstrate a sustained decrease in resting blood pressure with oral CBD dosing. More so, none have yielded evidence of the anti-inflammatory actions of CBD until Lexaria’s HYPER-H21-4 human clinical study Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced additional findings from its HYPER-H21-4 human clinical…

Continue Reading

Contact us: (310) 299-1717